Genentech, a member of the Roche Group, announced on Sunday that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted a priority review for the company’s obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for patients who have previously untreated follicular lymphoma.
Genentech, a member of the Roche Group, announced on Sunday that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted a priority review for the company’s obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for patients who have previously untreated follicular lymphoma.
The sBLA for obinutuzumab is based on the GALLIUM study, which demonstrated that treatment with the drug significantly improved progression-free survival (PFS) over rituximab-based treatment, the current standard of care.
The study, a global, phase 3, open-label, multicenter, randomized, 2-arm study, provided a head-to-head comparison with rituximab (also Genentech’s drug) plus chemotherapy, followed by rituximab alone, for up to 2 years. The GALLIUM study included 1401 patients with previously untreated indolent non-Hodgkin’s lymphoma, 1202 of whom had follicular lymphoma. The study’s primary endpoint was PFS in patients with follicular lymphoma (assessed by an investigator). Secondary endpoints included PFS as assessed by an independent review committee.
Results after the follow-up period of 41.1 months showed that obinutuzumab-based treatment reduced the risk of disease worsening or death by 32% (investigator assessment) or 28% (independent review committee assessment) compared to rituximab-based treatment.
The most common grade 3 to 5 adverse events that occurred more often with obinutuzumab than with rituximab were the following:
The drug maker says that it expects the FDA to make a decision on approval of the proposed indication by December 23, 2017. Roche has been focusing on the development of innovator drugs as it faces looming biosimilar competition for market share of its top 3 cancer drugs, bevacizumab (Avastin), trastuzumab (Herceptin), and rituximab (Mabthera, Rituxan), which jointly earned Roche $22.1 billion in sales in 2016.
News of obinutuzumab’s priority review follows another such announcement from Genentech on Wednesday; last week, the drug maker announced that the FDA had accepted a BLA and granted priority review for its emicizumab, a novel biologic for the treatment of hemophilia A in patients who have factor VIII inhibitors.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.